This company seems to have been delisted
Reason: Rebranded as Zevra Therapeutics
Last recorded trade on: May 3, 2023
Source: https://www.mmm-online.com/home/channel/kempharm-rebrands-to-zevra-therapeutics-doubling-down-on-rare-disease-focus/
Reason: Rebranded as Zevra Therapeutics
Last recorded trade on: May 3, 2023
Source: https://www.mmm-online.com/home/channel/kempharm-rebrands-to-zevra-therapeutics-doubling-down-on-rare-disease-focus/
KemPharm
KMPH
5,13 €
Share price
-0.34%
Change (1 day)
0.00%
Change (1 year)
Categories
Revenue for KemPharm (KMPH)
Revenue in 2022 (TTM): €9.88 Million
According to KemPharm's latest financial reports the company's current revenue (TTM 
) is €9.23 Million. In 2021 the company made a revenue of €25.29 Million an increase over the revenue in the year 2020 that were of €10.8 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for KemPharm from 2014 to 2022
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2022 (TTM) | €9.88 M | -60.94% |
| 2021 | €25.29 M | 134.17% |
| 2020 | €10.8 M | -5.74% |
| 2019 | €11.46 M | |
| 2018 | N/A | |
| 2017 | N/A | |
| 2016 | N/A | |
| 2015 | N/A | |
| 2014 | N/A |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 | €3.59 B | 38,807.53% | 🇮🇪 Ireland |
 | €19.04 M | 106.23% | 🇺🇸 USA |
 | €56.83 M | 515.61% | Cayman Islands |
 | €0.54 B | 5,774.70% | 🇺🇸 USA |